Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type
Authors:
- 9 August 2022
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (10) , 2353-2354
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataBlood Advances, 2022
- Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B‐cell lymphoma, leg typeBritish Journal of Haematology, 2019
- Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinibAnnals of Hematology, 2019
- A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg TypeJournal of Investigative Dermatology, 2018
- Clinical and biological significance ofde novoCD5+ diffuse large B-cell lymphoma in Western countriesOncotarget, 2015
- Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyJournal of Clinical Oncology, 2014
- European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomasBlood, 2008